Acessa Health Inc. Announces Presentations at the 46th Annual AAGL Global Congress on Minimally Invasive Gynecology

Four-Year Data on the Acessa® System to be Presented

AUSTIN, Texas–(BUSINESS WIRE)–#fibroidsAcessa
Health Inc
.
, developer of the Acessa® System, an innovative
laparoscopic radiofrequency ablation procedure for the treatment of
uterine fibroids, announced today that four-year data along with
community based evidence will be presented at the 46th Annual
Global Congress on Minimally Invasive Gynecology Meeting, Nov. 12-16 in
National Harbor, Greater Washington, D.C.

 

Tuesday, Nov. 14, 2017 from 1:09 PM – 1:15 PM

 
Title:     Laparoscopic Radiofrequency Ablation (Lap-RFA) of Symptomatic Myomas
and Laparoscopic Myomectomy (LM): Long-Term Outcomes from a
Randomized Trial of Uterine-Sparing Techniques
 
Authors: Bernard Krämer, MD; Felix Neis, MD; Andrei Taran, MD; Dorit
Schöller, MD; Keith B. Isaacson, MD; Sara Brucker, MD
 
 
Wednesday, Nov. 15, 2017 from 9:57 AM – 10:03 AM
 
Title:     Benefits to Treatment of Symptomatic Fibroids with Laparoscopic
Radiofrequency Ablation (Lap-RFA) Alone and Lap-RFA Plus Concomitant
Therapeutic Surgery: A Retrospective Comparative Cohort Analysis
 
Author: Alan Greenberg, MD
 

“We are thrilled with the continued positive and long-term accumulation
of clinical evidence associated with the Acessa procedure,” said Kim
Rodriguez, chief executive officer, Acessa Health. “Our team is
committed to transforming the delivery of women’s healthcare services
focused on the treatment of uterine fibroids. Our continued
collaboration with AAGL and clinical leaders across the field of
minimally invasive gynecologic surgeons is critical to ensure women have
broader access to the Acessa procedure.”

Symptomatic uterine fibroids are a significant societal and healthcare
burden, and there is no clear consensus among medical professionals as
to which procedural treatment is most appropriate for each symptomatic
patient.1 With an estimated cumulative incidence of up to 70%
and 80% in white and African American premenopausal women, respectively,
severe symptoms occur in 15 to 30% of these patients.2,3

Hysterectomy remains a primary treatment option for women who have
completed childbearing. It offers a complete solution to existing and
recurrent fibroids and concomitant disorders, including adenomyosis and
cervical neoplasia. However, adverse events are common among
hysterectomy patients. One study reported a 28% risk of complications
(such as major blood loss, wound complications, and febrile episodes) as
well as a 10% risk of transfusion among Medicaid patients undergoing
abdominal hysterectomy.4

Because of the invasiveness and observed risks associated with
hysterectomy, many women delay treatment. Most patients express a desire
for treatment that does not involve invasive surgery and preserves the
uterus.3

About the Acessa System

The Acessa System is the only radiofrequency ablation system cleared by
the U.S. Food and Drug Administration and CE marked for use in
percutaneous, laparoscopic coagulation and ablation of soft tissue,
including treatment of symptomatic uterine fibroids under laparoscopic
ultrasound guidance. It has been the subject of 21 peer-reviewed
publications across 750 study patients. In January 2017, the American
Medical Association (AMA) issued a new Category 1 CPT code specifically
for Laparoscopic Radiofrequency (RF) Ablation of Uterine Fibroids,
paving the way for the Acessa procedure to become the standard of care
for as many as 30 million women in the United States. For more
information, visit AcessaProcedure.com.

About Acessa Health Inc.

Acessa Health is a women’s health innovator dedicated to advancing
minimally invasive, uterine-sparing solutions for women with symptomatic
fibroids. The company introduced the use of radiofrequency ablation for
the treatment of uterine fibroids and is continuing to develop
technologies that improve the lives of its patients. Acessa’s
headquarters are in Austin, Texas.

______________________________________
1.     Havryliuk Y, Setton R, Carlow JJ, Shaktman BD. Symptomatic fibroid
management: systematic review of the literature. J Soc Laparoenosc
Surg.2017;21(3):e2017.00041
2. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High
cumulative incidence of uterine leiomyoma in black and white women:
ultrasound evidence. Am J Obstet Gynecol. 2003;188:100–7.
3. Borah BJ, Nicholson WK, Bradley L, Stewart EA. The impact of uterine
leiomyomas: a national survey of affected women. Am J Obstet
Gynecol. 2013;209:319.e1–319.e20.
4. Gliklich RE, Leavy MB, Velentgas P, et al. Identification of future
research needs in the comparative management of uterine fibroid
disease: a report on the priority-setting process, preliminary data
analysis, and research plan. Report No. 31. Rockville, MD. Agency
for Healthcare Research and Quality. 2011.

Contacts

Nobles Global Communications
Diana Soltesz, 818-618-5634
diana@noblesgc.com